ArticleJournal of gastrointestinal cancer2026
Implementing RAPIDO Protocol for Total Neoadjuvant Treatment of Carcinoma Rectum: A Real Life Experience from a Tertiary Care Cancer Center in India.
Article in Journal of gastrointestinal cancer, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeTotal Neoadjuvant treatment (TNT) has now become the standard of care in locally advanced rectal cancer(LARC) and has shown promising results. However, use and outcome of different TNT regimens in real-world practice is largely unknown.Here we report the feasibility and efficacy of RAPIDO regimen which we adopted since 2021 for LARC. MATERIALS AND
methodsA retrospective review of prospectively collected data, conducted at Tata Medical Center, Kolkata between January 2021 to June 2024. 95 consecutive patients with localized rectal adenocarcinoma, treated with short course radiotherapy 25 Gy/5frs/1week followed by CAPOX based chemotherapy with or without surgery were analysed. Data was collected in the Redcap Database.
resultsThe median age of the cohort was 53 years. Lower rectal disease, T4,N2,EMVI(Extramural Vascular Invasion) Grade 3/4, MRF (Mesorectal fascia) involvement were seen in 51(54%), 21(22.1%), 86(90.5%), 58(61%) and 70 (73.7%)patients respectively.62 patients (65.2%) underwent surgery. Pathological complete response (pCR) was achieved in 27.4%(17/62) cases. At a median follow-up of 2.4 years,43 patients (45.3%) underwent TNT and surgery and are disease free on follow up. Local failure was seen in 2 patients after surgery(3.2%)0.17 of 62 patients (27.4%) who underwent surgery developed distant metastasis with lung being the most common site (16.1%). The estimated 3 year overall survival of all patients was 83% and for patients who underwent surgery 3-year OS was 92% and 3-year disease free survival(DFS) was 63% Maximum grade≥ 3 diarrhoea and febrile neutropenia during chemotherapy were observed in 17 (17.9%) and 14 (14.7%) patients respectively.
conclusionRAPIDO protocol in real world settings shows excellent response rates in LARC. It is a safe and feasible approach, however implementing a prolonged neoadjuvant treatment in the real world remains a challenge because of suboptimal compliance.
Indexed as
Identifiers
42065776What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.